10 月，国内合计批签发血制品700.77 万瓶，同比增长17.10%；1-10 月，国内累计批签发血制品8244.80万瓶，同比增长15.61%。

1.月度批签发数据跟踪 .................................................................................................................................................. 6

1.1 总批签发情况............................................................................................................................................................ 6

1.2 各品种批签发情况 .................................................................................................................................................... 6

2.各品种批签发数据跟踪 ......................................................................................................................................... 7

2.1 人血白蛋白................................................................................................................................................................ 7

2.2 静注人免疫球蛋白（PH4） ..................................................................................................................................... 9

2.3 人免疫球蛋白.......................................................................................................................................................... 10

2.4 乙型肝炎人免疫球蛋白 .......................................................................................................................................... 10

2.5 破伤风人免疫球蛋白 ...............................................................................................................................................11

2.6 狂犬病人免疫球蛋白 .............................................................................................................................................. 12

2.7 人凝血因子VIII ...................................................................................................................................................... 13

2.8 人凝血酶原复合物 .................................................................................................................................................. 14

2.9 人纤维蛋白原 .......................................................................................................................................................... 15

3.上市公司批签发数据跟踪 ................................................................................................................................... 16

3.1 上海莱士 .................................................................................................................................................................. 16

3.2 华兰生物 .................................................................................................................................................................. 17

3.3 天坛生物 .................................................................................................................................................................. 18

3.4 卫光生物 .................................................................................................................................................................. 19

3.5 博雅生物 .................................................................................................................................................................. 20

3.6 双林生物 .................................................................................................................................................................. 21

4.投资建议 ......................................................................................................................................................................... 22

5.风险提示 ......................................................................................................................................................................... 23